Ocrevus 300 mg concentrate for solution for infusion
MN42988
Approved small_molecule active
Quick answer
Ocrevus 300 mg concentrate for solution for infusion for Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications] is a Approved program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]
- Phase
- Approved
- Modality
- small_molecule
- Status
- active